NCT05171686CompletedPhase 4
Diuretics and Volume Overload in Early CKD
Association of Diuretics With Change in Extracellular Volume, Natriuretic Peptides, Symptoms, and Cardiovascular Outcomes in CKD
Source: ClinicalTrials.gov · Last updated 21 Sept 2026
Brief summary (registry, in English)
Almost 15% of Americans have chronic kidney disease (CKD), with an even higher rate in Veterans due to common risk factors such as high blood pressure and diabetes. People with CKD have a high risk of cardiovascular (CV) diseases, such as heart attacks, heart failure, and strokes. Extra fluid in the body, called volume overload, may lead to CV disease in people with CKD. It is unknown if volume overload develops in the earliest stages of CKD, when treating it with common, inexpensive medicines called diuretics may improve long-term CV outcomes. This study will lay important groundwork to answer this question in Veterans with early CKD by comparing two ways to measure volume overload and studying the change in common symptoms like fatigue and short-term CV function after treatment with diuretic medicines.
- Status (registry)
- Completed
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 49 (actual)
- First submitted
- 1 Dec 2021
- Start date
- 1 Feb 2023
- Primary completion date
- 2 Oct 2025
- Lead sponsor
- VA Office of Research and Development
- NCT number
- NCT05171686
What you commit to
- Study type: Interventional · Phase 4
- Participants enrolled: 49
- From 1 Feb 2023 to the primary completion date, 2 Oct 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Receiving chronic hemodialysis or peritoneal dialysis.
- Recipient of a kidney transplant.
Lab values
- CKD stages 4-5, defined as eGFR \<30 mL/min/1.73 m2.
- Serum potassium \<3.5 mEq/L at baseline.
- Known left ventricular ejection fraction \<40% on visual estimate based on chart review of available echocardiogram data.
Other
- Unable to understand or provide informed consent.
- Unwilling or unable to participate in the protocol or comply with any of its components.
- Known hepatic cirrhosis.
- Major limb amputation.
- Known pregnancy.
- Presence of a pacemaker or defibrillator.
Who the study is looking for
- Male or female Veterans age 18 years or older. There will be no upper age limit.
- The presence of CKD stages 1, 2, or 3, as defined below by Kidney Disease Improving Global Outcomes guidelines, for a period of at least 3 months.
- Stage 1: eGFR 90 mL/min/1.73 m2 and spot urine albumin-to-creatinine ratio 30 mg/g.
- Stage 2: eGFR 60-89 mL/min/1.73 m2 and spot urine albumin-to-creatinine ratio 30 mg/g.
- Stage 3: eGFR 30-59 mL/min/1.73 m2.
- Measured blood pressure either \>140 mmHg systolic or \>90 mmHg diastolic at the two most recent clinic visits.
- Able to understand and sign informed consent after the nature of the study has been fully explained.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Michael E. DeBakey VA Medical Center, Houston, TX Coordinator of this site? Confirm its status | Houston | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.